What is the groundbreaking significance and mechanism of action of CTLA-4 antibodies as the first immune checkpoint inhibitors?

1. How did the "dual signal" model of T cell activation and early immune checkpoint theory form?

The core of adaptive immune response lies in the effective activation and regulation of T cells. As early as the 1970s, the scientific community established the classic "dual signal" model of T cell activation: Signal 1 originates from T cell receptor (TCR) recognition of specific antigen peptides presented by major histocompatibility complex (MHC); Signal 2 (or co-stimulatory signal) comes from the binding of B7 molecules (CD80/CD86) on antigen-presenting cells (APCs) to CD28 receptors on T cells. These two signals are indispensable, jointly ensuring the specificity and intensity of immune responses.

This seemingly perfect model received an important supplement in the late 1980s. Researchers discovered a transmembrane protein highly homologous to CD28 in structure, namely cytotoxic T lymphocyte-associated protein 4 (CTLA-4, CD152). Further studies revealed that CTLA-4 can also bind to B7 molecules, but with much higher affinity than CD28, and delivers a strong inhibitory signal upon binding. Therefore, CTLA-4 was established as a key negative regulatory molecule for T cell activation, an early "immune checkpoint." Its discovery clarified that the immune system has built-in "brakes" to prevent overactivation and autoimmune damage while maintaining immune homeostasis.

2. How did CTLA-4 antibodies evolve from theory to the first approved immune checkpoint drug?

Based on CTLA-4's inhibitory function, a revolutionary scientific concept emerged: in the tumor microenvironment, blocking CTLA-4's inhibitory signals could "release the brakes," reactivate T cells suppressed by tumors, and restore their ability to attack tumors. This hypothesis was validated in 1996 through mouse tumor model experiments, demonstrating that anti-CTLA-4 antibodies could induce effective anti-tumor immune responses.

Following this line of thought, the first fully human monoclonal antibody targeting CTLA-4—ipilimumab—was successfully developed. The clinical trial process was challenging, but it ultimately proved to significantly extend overall survival in patients with advanced melanoma. In 2011, ipilimumab was approved by the U.S. Food and Drug Administration (FDA), marking the dawn of a new era in cancer immunotherapy and establishing CTLA-4 antibodies as the "founding father" of immune checkpoint inhibitors. Its success paved the way for the development of more checkpoint inhibitors, such as PD-1/PD-L1 antibodies.

3. What are the fundamental differences between CTLA-4 antibodies and PD-1 antibodies in terms of mechanism and clinical characteristics?

Although both belong to immune checkpoint inhibitors, CTLA-4 antibodies and the later more successful PD-1/PD-L1 antibodies exhibit significant differences in mechanism, stage of action, and clinical features:

Stage and site of action:

- CTLA-4 antibodies: Primarily act during the early initiation phase of immune responses in lymph nodes. They block the binding of CTLA-4 to B7, weakening the early inhibition of naïve T cell activation, thereby promoting the generation and release of more effector T cells from lymphoid organs to peripheral tissues.

- PD-1 antibodies: Primarily act during the effector phase of immune responses in peripheral tissues and the tumor microenvironment. They block the binding of PD-1 to its ligands PD-L1/PD-L2, reversing the suppression of effector T cells that have infiltrated but are functionally exhausted in the tumor microenvironment, restoring their killing capacity.

Clinical characteristics:

- Efficacy spectrum: CTLA-4 antibodies (ipilimumab) are mainly effective in a few cancer types, such as melanoma, and have produced a cohort of long-term "super survivors." PD-1/PD-L1 antibodies exhibit broader anti-tumor activity, with approvals in dozens of cancers, including lung, liver, and kidney cancers.

- Safety profile: Immune-related adverse events (irAEs) induced by CTLA-4 antibodies typically occur earlier and are more severe, particularly colitis and hypophysitis. This is related to their early, systemic modulation of immune activation. PD-1 antibodies have a relatively lower incidence of irAEs and a different spectrum.

4. Are there more complex explanations for the mechanism of CTLA-4 antibodies?

As research deepens, more complex interpretations of the exact mechanism of CTLA-4 antibodies, especially ipilimumab, have emerged, going beyond simple "blocking inhibitory signals."

One important hypothesis focuses on regulatory T cells (Tregs). Tregs are a key cell subset that maintains immune tolerance and suppresses excessive immune responses, typically expressing high levels of CTLA-4. Studies suggest that the anti-tumor effects of CTLA-4 antibodies may be partly attributed to the effector functions mediated by their Fc region. Through antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP), CTLA-4 antibodies can selectively deplete Tregs highly expressing CTLA-4 in the tumor microenvironment, thereby lifting their suppression of effector T cells and reshaping the immune microenvironment. This mechanism highlights that, beyond their "blocking" function, the Fc-mediated clearance of effector cells by antibody drugs may also be crucial.

5. What is the current value of CTLA-4 antibodies in cancer immunotherapy?

Although PD-1/PD-L1 inhibitors have become the cornerstone of current cancer immunotherapy, CTLA-4 antibodies have not faded into history. Their unique value has been re-emphasized in combination therapy strategies.

Combination therapy strategies: Based on the complementary mechanisms of the two (CTLA-4 promotes T cell initiation and expansion, while PD-1 reverses T cell exhaustion), the combination of CTLA-4 antibodies and PD-1 antibodies has shown superior efficacy compared to either monotherapy in various cancers, including melanoma, renal cell carcinoma, and non-small cell lung cancer, albeit often with higher toxicity. This "powerful combination" strategy has become an important approach to tackling refractory tumors.

6. Which manufacturers provide CTLA-4 antibodies?

Hangzhou Start Biotech Co., Ltd. has independently developed "Anti-Human CTLA-4 Monoclonal Antibody (Ipilimumab Biosimilar)" (Catalog No.: S0B0564), a therapeutic antibody reference product with high bioactivity, high purity, and stringent quality standards. This product uses the originator drug ipilimumab as a reference and is prepared using an advanced mammalian cell expression system and refined downstream processes. It exhibits high similarity to the reference drug in key quality attributes, physicochemical properties, and biological functions, making it an indispensable core reagent for tumor immunotherapy research, drug mechanism exploration, bioanalysis, and drug development.

Professional technical support: We provide detailed product analysis reports, covering complete quality attribute data (purity, concentration, charge variants, glycan analysis, peptide mapping, etc.) and bioactivity validation reports. Our team of technical experts offers customized application solutions, fully supporting your innovative research and drug development in immuno-oncology.

Hangzhou Start Biotech Co., Ltd. is committed to providing high-quality, high-value bioactive macromolecules and solutions for global biopharmaceutical companies, research institutions, and clinical translation research. For more information about "Anti-Human CTLA-4 Monoclonal Antibody (Ipilimumab Biosimilar)" (Catalog No. S0B0564), technical documents, or collaboration inquiries, please feel free to contact us.

Product Information